Cargando…
Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus
Introduction: Quick release bromocriptine (BROM-QR), currently approved for glycemic control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus (T2DM). This study evaluates the effect of BROM-QR on homocysteine (HOMC) and high sensitive C-reactive protein (hs-CRP), th...
Autores principales: | Niafar, Mitra, Pourafkari, Leili, Shahsavarinia, Kavus, Milanchian, Nushin, Niafar, Farhad, Nader, Nader D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tabriz University of Medical Sciences
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827141/ https://www.ncbi.nlm.nih.gov/pubmed/27069561 http://dx.doi.org/10.15171/jcvtr.2016.02 |
Ejemplares similares
-
Metastatic medullary thyroid carcinoma: A case report
por: Niafar, Mitra, et al.
Publicado: (2011) -
Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes
por: Mahajan, Rajiv
Publicado: (2009) -
Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012) -
Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015) -
The therapeutic effect of bromocriptine as mesylate and estradiol valerate on serum and blood biochemistry of common quails
por: ul- Abideen, Zain, et al.
Publicado: (2021)